a2 Milk CEO David Bortolussi says China growth to continue as FY2026 China and other Asia revenue rises 11.2%

a2 Milk CEO David Bortolussi says China growth to continue as FY2026 China and other Asia revenue rises 11.2%

Summary

a2 Milk Company reported FY2026 revenue of NZ$1.975 billion, up 12.4 percent, with China and other Asia revenue rising 11.2 percent to NZ$1.4476 billion. In an interview at the China International Import Expo on 6 November, CEO David Bortolussi said China remains central to the company's global strategy and infant formula is one of its core categories for long-term growth in the market. Bortolussi said a2 uses genetic testing to identify cows that naturally produce only A2 beta-casein and no A1 protein, and has built a separate supply chain covering farm storage, transport, processing and finished-product filling.

All products are made in New Zealand and meet both Chinese and New Zealand regulatory standards. a2 recently completed the acquisition and upgrade of its Pokeno plant in New Zealand's North Island, a comprehensive facility with total investment of several hundred million New Zealand dollars. Over the past five years, a2 has expanded its core product range from 7 to 32, with innovation contributing more than half of sales growth.

At this year's CIIE, a2 launched three new infant formula products for the China market: a2 Platinum Zhi Chu Qi Run, a2 Platinum Zhi Chu Zhi Chun and the new-generation a2 Zi Bai Jin series. Bortolussi said a2 plans to add two more products in the coming years, with timing and details still being finalised, and will continue to deepen core channels in China including mother-and-baby stores, domestic online channels and cross-border e-commerce.

Commentary

a2 Milk Company's 12.4 percent revenue growth in FY2026, with China and Asia contributing more than 70 percent, underscores its deep reliance on the China market. As the pioneer of the A2 protein category, a2 has built technical barriers through genetic testing and a dedicated supply chain, but global infant formula market growth is slowing, China's birth rate continues to decline and competition is intensifying. Giants such as Fonterra and Danone are moving into the A2 segment, challenging a2's first-mover advantage.

For New Zealand small and medium-sized enterprises, a2's supply chain localisation strategy offers a useful reference: its Pokeno plant upgrade, with investment of several hundred million New Zealand dollars, ensures products meet both Chinese and New Zealand standards, and this 'Made in New Zealand plus Chinese standards' model provides a compliance template for smaller dairy firms entering China. At the same time, innovation contributing more than half of growth shows differentiated products still have breakout potential in a mature market. However, over-reliance on a single market carries risks, as changes in Chinese regulatory policy or consumer fluctuations could directly affect company performance.

New Zealand businesses should watch how a2 balances China localisation with global expansion, and learn from its refined operations in cross-border e-commerce and mother-and-baby channels, which offer valuable lessons for local companies seeking to enter the China market.

Keywords: a2 Milk Company, David Bortolussi, China and other Asia, infant formula, A2 beta-casein, China International Import Expo, Pokeno plant, FY2026 results


AI illustration on MiDeer Observer

Source: Phoenix Weekly

Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.

Leave a Reply

Your email address will not be published. Required fields are marked *